Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shedding Earlier Fears, Pharma Takes A Fresh Look At Cell, Gene Therapies

Executive Summary

The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.


Related Content

Reinventing Cell Therapy And Biomaterials
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy
Newly Appointed Head of Regenerative Medicine At Shire Plans Rapid Growth For The Division
As Provenge Sales Dip, Dendreon Hopes Restructuring Is The Answer
Aiming For More Deals, Shire Christens Regenerative Medicine Unit
Disappointing Provenge Sales Stir Doubts About Demand
Advanced BioHealing To Bring Regeneration To Shire


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts